The Ledger

1 billion dollars: that is how much debt a dental support organization just erased by handing the keys to the private credit firms that financed its 2021 buyout, wiping out the private equity firm that bought it. Affordable Care, LLC, the parent of Affordable Dentures & Implants and the largest tooth-replacement-focused dental support organization in the country, completed a creditor-led recapitalization on August 13, 2026 that cuts its debt load by approximately 1.0 billion dollars, roughly 65 percent, while injecting 75 million dollars in new capital and extending maturities to 2031. The company’s existing lenders, a group that includes Blackstone as the largest debt holder and KKR, which also agented the original financing, take over ownership; Harvest Partners, which bought Affordable Care for approximately 2.7 billion dollars in 2021 with about 1.4 billion dollars in private credit financing, is not mentioned in the company’s own announcement, and Blackstone has said it first marked the loan down 18 months ago before cutting its valuation further, to 70 cents on the dollar in the first quarter of 2026, ahead of the restructuring. Affordable Care says its 380-plus affiliated practices across 39 states and its existing management team, led by chief executive Pete Bridgman, continue unchanged. Confidence: High on the transaction terms, which come directly from Affordable Care’s own release; Medium on the specific lender roles and the outcome for Harvest Partners’ equity, which this run confirmed through financial press reporting on the lenders’ own debt markdowns rather than the company’s statement. Sources: Affordable Care Completes Strategic Transaction to Strengthen Financial Foundation and Support Future Growth, Affordable Care LLC via Yahoo Finance, Affordable Care being restructured after private credit markdowns, Yahoo Finance.

3 million: that is how many patients a newly combined dermatology group will treat each year, after two of the field’s largest platforms merged without disclosing a price. DermCare Management and U.S. Dermatology Partners completed a strategic combination on August 13, 2026, creating what the companies call one of the largest dermatology group practices in the United States. DermCare brings more than 270 providers and over 1 million patients across Florida, Texas, Virginia, North Carolina and California; U.S. Dermatology Partners treats more than 2 million patients across nine states; together the combined organization spans 12 states. DermCare founder and chief executive Jeffrey Schillinger becomes executive chair of the combined company, while U.S. Dermatology Partners chief executive Paul Singh becomes president and chief executive of the combined entity; both companies remain privately held and did not disclose financial terms. Confidence: High on the deal structure and patient/provider counts, which come directly from the companies’ own release; the absence of disclosed financial terms means the transaction’s value cannot be independently verified this run. Source: DermCare Management and U.S. Dermatology Partners Complete Strategic Transaction to Combine Operations, Creating One of the Largest Dermatology Group Practices in the U.S., via Yahoo Finance.

34 percent: that is the premium a private equity firm is paying to take a healthcare communications software company private, one day after its shares closed at an “unaffected” price. Francisco Partners agreed August 18, 2026 to acquire Weave Communications, an AI-powered patient engagement and payments platform used by dental, medical, veterinary and other healthcare practices, for approximately 650 million dollars in an all-cash take-private deal. Weave shareholders will receive 7.40 dollars per share, a roughly 34 percent premium to the company’s unaffected closing price on August 17, 2026; the Weave board approved the deal unanimously, and the transaction, expected to close in the fourth quarter of 2026, still requires stockholder and regulatory approval. Weave will keep its headquarters in Lehi, Utah and continue operating under its own name once it goes private. Confidence: High. The deal terms come directly from Weave’s own investor relations release. Source: Weave Announces Acquisition by Francisco Partners, Weave Communications investor relations.

65 million dollars: that is the trailing revenue of a tele-ICU company an ambulance and mobile-health operator is absorbing, assuming 52 million dollars of its debt to get the deal done. DocGo announced August 16, 2026 a definitive agreement to acquire Hicuity Health, a provider of tele-ICU, virtual nursing and telemetry monitoring services for hospitals, health systems and post-acute facilities, structured as a tax-free reorganization in which Hicuity’s Series F preferred stockholder receives DocGo stock equal to 2.0 percent of DocGo’s fully diluted shares at closing plus a 3.5 percent earnout tied to DocGo reaching a 250 million dollar market capitalization within three years; other Hicuity equity holders, options and warrants are cancelled for no consideration. DocGo will assume approximately 52 million dollars of Hicuity’s existing term loans from Perceptive Credit Holdings, now maturing in December 2029, and Perceptive has separately committed up to 50 million dollars in new financing to DocGo across three tranches. Hicuity generated approximately 65 million dollars in trailing 12-month revenue and 4.5 million dollars in adjusted EBITDA; DocGo chief executive Lee Bienstock called the deal a step toward becoming “the premier provider of virtual, remote, and in-home healthcare.” Confidence: High. The deal terms come directly from DocGo’s own SEC filing. Source: DocGo Inc., Form 8-K, U.S. Securities and Exchange Commission via StockTitan.

HER2: that is the cancer marker a radiopharmaceutical company just bought its way into imaging, in a quiet deal with no disclosed price tag. Curium, a global radiopharmaceutical maker, announced August 10, 2026 it had completed the acquisition of Abscint SA, a Belgian clinical-stage radiopharmaceutical company, gaining global rights to develop, manufacture and commercialize ABS-011, an investigational gallium-68-labeled PET radiodiagnostic tracer designed to target HER2, a biological marker present in some breast and gastric cancers. The deal extends a wave of radiopharmaceutical dealmaking this newsletter has tracked since August, when Nordic Capital agreed to buy up to 800 million dollars of BWX Technologies’ medical isotope business; Curium did not disclose financial terms for the Abscint transaction. Confidence: High on the deal’s existence and the asset acquired, which come directly from Curium’s own release; Low on the deal’s value, which was not disclosed. Source: Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology, Curium Pharma.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Affordable Care, LLC	Existing private-credit lenders (Blackstone largest holder, KKR agent)	Dental service organization, distressed recapitalization	Approximately $1.0 billion debt reduction (about 65%) plus $75 million new capital; completed August 13, 2026	Affordable Care Completes Strategic Transaction, Affordable Care LLC via Yahoo Finance
DermCare Management	U.S. Dermatology Partners (strategic combination)	Dermatology group practice roll-up	Undisclosed; completed August 13, 2026	DermCare Management and U.S. Dermatology Partners Complete Strategic Transaction, via Yahoo Finance
Weave Communications	Francisco Partners	Healthcare patient engagement and payments software	Approximately $650 million, $7.40/share cash, 34% premium; announced August 18, 2026, expected to close Q4 2026	Weave Announces Acquisition by Francisco Partners, Weave Communications investor relations
Hicuity Health	DocGo	Digital health, tele-ICU and virtual nursing	Stock consideration (2.0% closing plus 3.5% earnout) plus assumption of approximately $52 million in debt; announced August 16, 2026	DocGo Inc., Form 8-K, SEC via StockTitan
Abscint SA	Curium	Radiopharmaceutical, PET oncology imaging	Undisclosed; completed August 10, 2026	Curium acquires Abscint SA, Curium Pharma

This run’s scan of PE Hub, Axios Pro Rata, FTC and DOJ merger actions and state transaction-review dockets found the five transactions above; no new FTC or DOJ healthcare antitrust actions were spotted in the last 24 to 48 hours.